Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
10.3971/j.issn.1000-8578.2022.22.0145
- VernacularTitle:免疫检查点抑制剂相关肺炎研究进展
- Author:
Shuangqing CHEN
1
;
Wenbo WU
;
Chaohui HAN
;
Shumin CAO
;
Xiaopeng ZHANG
;
Guochen DUAN
Author Information
1. Department of Thoracic Surgery, Hebei People's Hospital, Shijiazhuang 050057, China
- Publication Type:Research Article
- Keywords:
Lung cancer;
Immunotherapy;
Immune checkpoint inhibitors;
Checkpoint inhibitor pneumonitis
- From:
Cancer Research on Prevention and Treatment
2022;49(10):1065-1070
- CountryChina
- Language:Chinese
-
Abstract:
With the research progress on the biology and pathogenesis of cancer, immune checkpoint inhibitors (ICIs) have come into being, bringing a new hope for the survival of patients with advanced cancer and opening a new era of cancer immunotherapy. However, with the wide application of immunotherapy in clinical practice, ICI-related adverse events (irAEs) have gradually emerged and are widely known by first-line clinicians. ICIs primarily activate T cells that can attack normal tissues and organs in the body and cause a variety of adverse reactions. Checkpoint inhibitor pneumonitis (CIP) is one of the rare complications with poor prognosis in irAEs. This article reviews the therapeutic mechanism of some ICIs; the incidence, risk factors, pathogenesis, and clinical and imaging manifestations of CIP; and the classification and treatment management of CIP.
